Myelodysplastic syndromes are a group of blood disorders that affect how bone marrow makes blood cells. MDS can lead to low blood cell counts (cytopenia), and the cells in bone marrow not developing properly (dysplasia). MDS can also increase the risk of developing acute myeloid leukemia (AML) later on.
In 2022, the World Health Organization (WHO) updated the classification of MDS to better understand the disease.
MDS with defining genetic abnormalities:
MDS, morphologically defined (structural abnormalities in the cells):
Childhood MDS:
The WHO classification system of MDS is based on clinical features, peripheral blood, bone marrow findings, and cytogenetic analysis. This classification of myeloid neoplasms also includes another diverse mix of neoplasms that share some features with myelodysplastic syndromes and can be treated similarly.
Chronic myelomonocytic leukemia (CMML)
The WHO classification system helps healthcare professionals to provide more accurate diagnoses and implement personalized treatment strategies. Collaborative efforts between researchers, clinicians, and patients will further our understanding of these disorders and drive progress toward improved treatment options and, ultimately, better outcomes for those affected by Myelodysplastic Syndromes.
Reference:
https://emedicine.medscape.com/article/2007806-overview?form=fpf
Myelodysplastic syndromes are a group of blood disorders that affect how bone marrow makes blood cells. MDS can lead to low blood cell counts (cytopenia), and the cells in bone marrow not developing properly (dysplasia). MDS can also increase the risk of developing acute myeloid leukemia (AML) later on.
In 2022, the World Health Organization (WHO) updated the classification of MDS to better understand the disease.
MDS with defining genetic abnormalities:
MDS, morphologically defined (structural abnormalities in the cells):
Childhood MDS:
The WHO classification system of MDS is based on clinical features, peripheral blood, bone marrow findings, and cytogenetic analysis. This classification of myeloid neoplasms also includes another diverse mix of neoplasms that share some features with myelodysplastic syndromes and can be treated similarly.
Chronic myelomonocytic leukemia (CMML)
The WHO classification system helps healthcare professionals to provide more accurate diagnoses and implement personalized treatment strategies. Collaborative efforts between researchers, clinicians, and patients will further our understanding of these disorders and drive progress toward improved treatment options and, ultimately, better outcomes for those affected by Myelodysplastic Syndromes.
Reference:
https://emedicine.medscape.com/article/2007806-overview?form=fpf
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.